Molecular Partners AG MOLN
Regular-session close
After hours · Nov 19, 4:10 PM ET
- YTD
- -42.89%
- 1 year
- -40.57%
5D -0.04 (-1.38%)
- Market cap
- 102.16M
- Revenue (ttm)
- 6.00M
- EPS (ttm)
- -1.68
- Shares out
- 36.86M
- Forward P/E
- -2.96
- YTD return
- -42.89%
- 1-year return
- -40.57%
- 50-day average
- 5.63
- Volume
- 93
- Avg volume
- 1.69K
- Open
- 2.77
- Previous close
- 2.67
- Day's range
- 2.67 – 2.77
- 52-week range
- 2.63 – 5.36
- Beta
- 0.54
- Price target
- 10.37 (+316.6%)
Key statistics
- 200-day average
- 5.30
- Enterprise value
- 27.75M
- Price / sales
- 33.41
- Price / book
- 1.30
- Revenue growth
- -73.20%
- Free cash flow
- -38.46M
- Total cash
- 143.62M
- Total debt
- 2.75M
- Return on equity
- -37.37%
- Short % of float
- 0.21%
Fundamental scorecard
4 of 25 checks passed on MOLN’s reported financials
4of 25 checks passed
- Value 0 of 5
- Growth 1 of 5
- Profitability 0 of 5
- Financial health 3 of 5
- Dividend No data
Statements to Sep 30, 2026.
Financials — quick view
Earnings
| Report date | Quarter ending | EPS estimate | EPS reported | Surprise | Surprise % |
|---|---|---|---|---|---|
| Oct 31, 2024 | Sep 1, 2024 | -0.63 | -0.57 | +0.06 | +9.52% |
| Aug 26, 2024 | Jun 1, 2024 | 0.00 | -0.51 | — | — |
| Aug 26, 2024 | Jun 1, 2024 | 0.00 | — | — | — |
| May 16, 2024 | Mar 1, 2024 | 0.00 | -0.39 | — | — |
| May 16, 2024 | Mar 1, 2024 | 0.00 | — | — | — |
| Mar 14, 2024 | Dec 1, 2023 | 0.00 | — | — | — |
Upgrades / downgrades
| Date | Firm | Action | From | To |
|---|---|---|---|---|
| Dec 5, 2023 | JP Morgan | main | Neutral | Neutral |
| Aug 29, 2022 | SVB Leerink | down | Outperform | Market Perform |
| May 25, 2022 | Credit Suisse | up | Underperform | Neutral |
| Apr 27, 2022 | SVB Leerink | main | — | Outperform |
| Jan 14, 2022 | SVB Leerink | main | — | Outperform |
| Aug 27, 2021 | SVB Leerink | main | — | Outperform |
About Molecular Partners AG
Molecular Partners AG, a clinical-stage biotechnology company, develops designed ankyrin repeat proteins therapeutics for the treatment of oncology and virology diseases in Switzerland. The company develops MP0317, a CD40 agonist designed to activate immune cells within the tumor microenvironment by anchoring to fibroblast activation protein that is in Phase I clinical trial; and MP0533, a novel tetra-specific T cell-engaging DARPin for acute myeloid leukemia. It also develops Switch-DARPin platform, a multispecific cKIT x CD16a x CD47 Switch-DARPin program for targeted and conditional immune cell activation; and Radio-DARPin Therapy (RDT) platform, a delivery system for effective and selective delivery of radioactive payloads to solid tumors. It has license and research collaboration agreements with Novartis Pharma AG to develop DARPin-conjugated radioligand therapies; and collaboration agreement with Orano Med SAS to develop novel Radio-DARPin therapeutics. Molecular Partners AG was incorporated in 2004 and is headquartered in Schlieren, Switzerland.
- Sector
- Healthcare
- Industry
- Biotechnology
- Country
- Switzerland
- Website
- molecularpartners.com
News
Molecular Partners to Present at Inaugural UBS Global Biopharma Conference Molecular Partners Says MP0632 Preclinical Data At SITC 2026 Show No Detectable Impact On Healthy Mesothelial Or Epithelial Cells, Supporting IND-Enabling Studies In MSLN And EpCAM Solid Tumors
Molecular Partners Q3 EPS $(0.38) Beats $(0.46) Estimate
Your note
Sign in to keep a note on MOLN — it syncs with the Stock Master app.
Institution ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| BVF Inc. | 1.10% | 443,221 | 2.41M | Sep 29, 2024 |
| Suvretta Capital Management, LLC | 0.99% | 400,000 | 2.18M | Sep 29, 2024 |
| UBS Group AG | 0.01% | 5,246 | 28.54K | Sep 29, 2024 |
| Rhumbline Advisers | 0.00% | 269 | 1.46K | Sep 29, 2024 |
| Morgan Stanley | 0.00% | 500 | 2.72K | Sep 29, 2024 |
Fund ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| Fidelity NASDAQ Composite Index Fund | 0.00% | 1,070 | 5.82K | Oct 30, 2024 |
